Top

Systematic Reviews

Published in:

Open Access 01-12-2024 | Rectal Cancer | Systematic review update

Prognostic impact of tumor budding in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis

Authors: Jinghui Li, Yongli Ma, Liang Wen, Guosheng Zhang, Chengzhi Huang, Junjiang Wang, Xueqing Yao

Published in: Systematic Reviews | Issue 1/2024

Abstract

Background

Tumor budding (TB) is a negative prognostic factor in colorectal cancer; however, its prognostic impact following neoadjuvant therapy for patients with rectal cancer remains unclear. This study aims to assess the prognostic impact of TB and the correlation between TB and other pathological features in patients with rectal cancer after neoadjuvant therapy.

Methods

A comprehensive search of PubMed, Embase, Cochrane, Scopus, CNKI, Wanfang, and ClinicalKey databases was conducted for studies on the prognosis of TB in rectal cancer after neoadjuvant therapy from the inception of the databases to January 2023, and the final literature included was determined using predefined criteria. Quality assessment of the studies included, extraction of general and prognostic information from them, and meta-analyses were carried out progressively.

Results

A total of 11 studies were included, and the results of the meta-analysis showed that high-grade tumor budding (TB-1) increased the risk of poor 5-year disease-free survival (HR = 1.75, 95% CI 1.38–2.22, P < 0.00001), 5-year overall survival (HR = 1.77, 95% CI 1.21–2.59, P = 0.003), local recurrence (OR = 4.15, 95% CI 1.47–11.75, P = 0.007), and distant metastasis (OR = 5.36, 95% CI 2.51–11.44, P < 0.0001) in patients with rectal cancer after neoadjuvant therapy. TB-1 was significantly associated with poor differentiation and lymphatic, perineural, and venous invasion.

Conclusion

Tumor budding is significantly correlated with unfavorable prognosis and poor pathological characteristics following neoadjuvant therapy for rectal cancer. We anticipate more high-quality, prospective studies in the future to confirm our findings.

Systematic review registration

PROSPERO CRD42022377564.

Available only for authorised users

Fadel MG, Ahmed M, Malietzis G, Pellino G, Rasheed S, Brown G, et al. Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: a systematic review. Cancer Treat Rev. 2022;109:102419. https://doi.org/10.1016/j.ctrv.2022.102419.CrossRefPubMed

Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17(7):414–29. https://doi.org/10.1038/s41575-020-0275-y.CrossRefPubMed

Kennecke HF, Bahnson HT, Lin B, O’Rourke C, Kaplan J, Pham H, et al. Patterns of practice and improvements in survival among patients with stage 2/3 rectal cancer treated with trimodality therapy. JAMA Oncol. 2022;8(10):1466–70. https://doi.org/10.1001/jamaoncol.2022.2831.CrossRefPubMedPubMedCentral

Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(1):38–48. https://doi.org/10.1016/S2468-1253(21)00348-4.CrossRefPubMed

Socha J, Żółciak-Siwińska A, Bujko K. Radio- or chemotherapy dose escalation for organ preservation in rectal cancer? J Clin Oncol. 2023;41(2):417. https://doi.org/10.1200/JCO.22.01296.CrossRefPubMed

Goffredo P, Khan A, Mott SL, Jensen CC, Madoff RD, Gaertner WB, et al. Total neoadjuvant therapy versus standard neoadjuvant chemoradiation in patients with locally advanced rectal cancer: a comparison of short- and long-term oncologic outcomes. Ann Surg. 2022;276(6):e819–24. https://doi.org/10.1097/SLA.0000000000005141.CrossRefPubMed

Dhadda A, Sun Myint A, Thamphya B, Hunter I, Hershman M, Gerard JP. A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision - preliminary results of the CONTEM1 study. Radiother Oncol. 2021;162:195–201. https://doi.org/10.1016/j.radonc.2021.07.021.CrossRefPubMed

Fokas E, Glynne-Jones R, Fleischmann M, Piso P, Tselis N, Ghadimi M, et al. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: lessons from studies in fit patients and future perspectives. Cancer Treat Rev. 2023;112:102490. https://doi.org/10.1016/j.ctrv.2022.102490.CrossRefPubMed

Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, et al. Rectal cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139–67. https://doi.org/10.6004/jnccn.2022.0051.CrossRefPubMed

10.

Saraf A, Roberts HJ, Wo JY, Parikh AR. Optimal neoadjuvant strategies for locally advanced rectal cancer by risk assessment and tumor location. J Natl Compr Canc Netw. 2022;20(10):1177–84. https://doi.org/10.6004/jnccn.2022.7061.CrossRefPubMed

11.

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30(9):1299–311. https://doi.org/10.1038/modpathol.2017.46.CrossRefPubMed

12.

Wen X, Zee SY, Shroyer KR, Bandovic J. Intratumoral budding and tumor microenvironment in pretreatment rectal cancer biopsies predict the response to neoadjuvant chemoradiotherapy. Appl Immunohistochem Mol Morphol. 2022;30(1):1–7. https://doi.org/10.1097/PAI.0000000000000966.CrossRefPubMed

13.

Farchoukh L, Hartman DJ, Ma C, Celebrezze J, Medich D, Bahary N, et al. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma. Mod Pathol. 2021;34(1):171–83. https://doi.org/10.1038/s41379-020-0619-8.CrossRefPubMed

14.

Dykstra MA, Gimon TI, Ronksley PE, Buie WD, MacLean AR. Classic and novel histopathologic risk factors for lymph node metastasis in T1 colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum. 2021;64(9):1139–50. https://doi.org/10.1097/DCR.0000000000002164.CrossRefPubMed

15.

Zwager LW, Bastiaansen BAJ, Montazeri NSM, Hompes R, Barresi V, Ichimasa K, et al. Deep submucosal invasion is not an independent risk factor for lymph node metastasis in T1 colorectal cancer: a meta-analysis. Gastroenterology. 2022;163(1):174–89. https://doi.org/10.1053/j.gastro.2022.04.010.CrossRefPubMed

16.

Shivji S, Cyr DP, Pun C, Duan K, Sari A, Tomin R, et al. A novel combined tumor budding-poorly differentiated clusters grading system predicts recurrence and survival in stage I-III colorectal cancer. Am J Surg Pathol. 2022;46(10):1340–51. https://doi.org/10.1097/PAS.0000000000001920.CrossRefPubMed

17.

Garfinkle R, Lee L, Boutros M, Cardin MJ, Spatz A, Morin N. Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer. Can J Surg. 2019;62(5):334–9. https://doi.org/10.1503/cjs.019017.CrossRefPubMedPubMedCentral

18.

Du C, Xue W, Li J, Cai Y, Gu J. Morphology and prognostic value of tumor budding in rectal cancer after neoadjuvant radiotherapy. Hum Pathol. 2012;43(7):1061–7. https://doi.org/10.1016/j.humpath.2011.07.026.CrossRefPubMed

19.

Chen W, Farchoukh L, Seigh L, Hartman DJ, Pai RK. Combined histopathological risk score using TP53 protein expression, CD8+ T cell density and intratumoral budding is an independent predictor of neoadjuvant therapy response in rectal adenocarcinoma. Histopathology. 2021;79(5):826–35. https://doi.org/10.1111/his.14430.CrossRefPubMed

20.

Rogers AC, Gibbons D, Hanly AM, Hyland JM, O’Connell PR, Winter DC, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol. 2014;27(1):156–62. https://doi.org/10.1038/modpathol.2013.124.CrossRefPubMed

21.

Jäger T, Neureiter D, Fallaha M, Schredl P, Kiesslich T, Urbas R, et al. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. Strahlenther Onkol. 2018;194(11):991–1006. https://doi.org/10.1007/s00066-018-1340-0.CrossRefPubMedPubMedCentral

22.

Huh JW, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, et al. Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy. Surgery. 2019;165(3):579–85. https://doi.org/10.1016/j.surg.2018.08.026.CrossRefPubMed

23.

Trotsyuk I, Sparschuh H, Müller AJ, Neumann K, Kruschewski M, Horst D, et al. Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy. BMC Cancer. 2019;19(1):1033. https://doi.org/10.1186/s12885-019-6261-5.CrossRefPubMedPubMedCentral

24.

Swets M, Kuppen PJK, Blok EJ, Gelderblom H, van de Velde CJH, Nagtegaal ID. Are pathological high-risk features in locally advanced rectal cancer a useful selection tool for adjuvant chemotherapy? Eur J Cancer. 2018;89:1–8. https://doi.org/10.1016/j.ejca.2017.11.006.CrossRefPubMed

25.

Huebner M, Wolff BG, Smyrk TC, Aakre J, Larson DW. Partial pathologic response and nodal status as most significant prognostic factors for advanced rectal cancer treated with preoperative chemoradiotherapy. World J Surg. 2012;36(3):675–83. https://doi.org/10.1007/s00268-011-1409-8.CrossRefPubMed

26.

Demir A, Alan O, Oruc E. Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment. World J Surg Oncol. 2019;17(1):50. https://doi.org/10.1186/s12957-019-1588-6.CrossRefPubMedPubMedCentral

27.

Shin JK, Park YA, Huh JW, Yun SH, Kim HC, Lee WY, et al. Tumor budding as a prognostic marker in rectal cancer patients on propensity score analysis. Ann Surg Oncol. 2021;28(13):8813–22. https://doi.org/10.1245/s10434-021-10286-6.CrossRefPubMed

28.

Huh JW, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, et al. Mismatch repair gene expression as a predictor of tumor responses in patients with rectal cancer treated with preoperative chemoradiation. Medicine (Baltimore). 2016;95(3):e2582. https://doi.org/10.1097/MD.0000000000002582.CrossRefPubMed

29.

Kim S, Huh JW, Lee WY, Yun SH, Kim HC, Cho YB, et al. Prognostic impact of lymphatic invasion, venous invasion, perineural invasion and tumor budding in rectal cancer treated with neoadjuvant chemoradiotherapy followed by total mesorectal excision. Dis Colon Rectum. 2022. https://doi.org/10.1097/DCR.0000000000002266.CrossRefPubMed

30.

Huang LB, Yang TH, Chen HN. Predictive role of tumor budding in T1 colorectal cancer lymph node metastasis. Gastroenterology. 2021;161(2):732–3. https://doi.org/10.1053/j.gastro.2020.12.053.CrossRefPubMed

31.

van Wyk HC, Roseweir A, Alexander P, Park JH, Horgan PG, McMillan DC, et al. The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer. Ann Surg Oncol. 2019;26(13):4397–404. https://doi.org/10.1245/s10434-019-07931-6.CrossRefPubMedPubMedCentral

32.

Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right- and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis. 2011;13(8):884–9. https://doi.org/10.1111/j.1463-1318.2010.02356.x.CrossRefPubMed

33.

Hodges N, Mackenzie H, D’Souza N, Brown G, Miskovic D. Survival outcomes for right-versus left-sided colon cancer and rectal cancer in England: a propensity-score matched population-based cohort study. Eur J Surg Oncol. 2022;48(4):841–9. https://doi.org/10.1016/j.ejso.2021.10.007.CrossRefPubMed

34.

Patel M, McSorley ST, Park JH, Roxburgh CSD, Edwards J, Horgan PG, et al. The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer. Br J Cancer. 2018;118(5):705–12. https://doi.org/10.1038/bjc.2017.441.CrossRefPubMedPubMedCentral

35.

Grüter AAJ, van Lieshout AS, van Oostendorp SE, Ket JCF, Tenhagen M, den Boer FC, et al. Required distal mesorectal resection margin in partial mesorectal excision: a systematic review on distal mesorectal spread. Tech Coloproctol. 2023;27(1):11–21. https://doi.org/10.1007/s10151-022-02690-1.CrossRefPubMed

36.

Tamburini E, Tassinari D, Ramundo M, De Stefano A, Viola MG, Romano C, et al. Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2022;172:103627. https://doi.org/10.1016/j.critrevonc.2022.103627.CrossRefPubMed

37.

Zhang X, Ma S, Guo Y, Luo Y, Li L. Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis of 15 trials. PLoS One. 2022;17(11):e0276599. https://doi.org/10.1371/journal.pone.0276599.CrossRefPubMedPubMedCentral

Title: Prognostic impact of tumor budding in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis
Authors: Jinghui Li
Yongli Ma
Liang Wen
Guosheng Zhang
Chengzhi Huang
Junjiang Wang
Xueqing Yao
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Rectal Cancer
Rectal Cancer
Published in: Systematic Reviews / Issue 1/2024
Electronic ISSN: 2046-4053
DOI: https://doi.org/10.1186/s13643-023-02441-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic impact of tumor budding in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusion

Systematic review registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Systematic review registration

Please log in to get access to this content

Other articles of this Issue 1/2024

Tools for assessing the methodological limitations of a QES—a short note

Natural language processing (NLP) to facilitate abstract review in medical research: the application of BioBERT to exploring the 20-year use of NLP in medical research

Predictors of cocaine use disorder treatment outcomes: a systematic review

Use of digital media by adolescents for sexual and reproductive health and rights communication in sub-Saharan Africa: a protocol for systematic review

The effect of acupuncture on oxidative stress in animal models of vascular dementia: a systematic review and meta-analysis

Prevalence of thyroid dysfunction and associated factors among adult type 2 diabetes mellitus patients, 2000–2022: a systematic review and meta-analysis